Declared Dividend • May 20
Dividend increased to CHF4.70 Dividend of CHF4.70 is 6.8% higher than last year. Ex-date: 19th June 2026 Payment date: 23rd June 2026 Dividend yield will be 2.3%, which is higher than the industry average of 0.7%. Sustainability & Growth Dividend is covered by both earnings (52% earnings payout ratio) and cash flows (46% cash payout ratio). The dividend has increased by an average of 8.4% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 34% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Live News • May 19
Sonova Eyes Further Growth With Record Dividend After Robust Earnings and Business Refocus Sonova reported FY25/26 sales growth of 5.9% in local currencies and a 17.3% rise in normalized EBITA, with performance mainly driven by its Hearing Instruments segment and cost discipline.
The company plans to divest its Consumer Hearing business and has reorganized regional operations to sharpen focus and improve agility.
Management proposed a record dividend and is guiding for FY26/27 sales growth of 5% to 8% and core EBIT growth of 7% to 10%, supported by ongoing efficiency efforts, product development and targeted M&A.
The combination of higher profitability, a record dividend and a clear focus on core hearing activities signals management’s confidence in Sonova’s current positioning and operating model.
Readers should watch how the Consumer Hearing divestment and cochlear implants challenges play out, since execution around these areas and future acquisitions could influence margins, growth and risk profile. Announcement • May 19
Sonova Holding AG, Annual General Meeting, Jun 16, 2026 Sonova Holding AG, Annual General Meeting, Jun 16, 2026, at 09:30 W. Europe Standard Time. Reported Earnings • May 19
Full year 2026 earnings: EPS and revenues miss analyst expectations Full year 2026 results: EPS: CHF9.02 (down from CHF9.37 in FY 2025). Revenue: CHF3.61b (flat on FY 2025). Net income: CHF537.1m (down 3.8% from FY 2025). Profit margin: 15% (in line with FY 2025). Revenue missed analyst estimates by 3.5%. Earnings per share (EPS) also missed analyst estimates by 17%. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 7% per year and the company’s share price has also fallen by 7% per year. Announcement • Dec 18
Sonova Holding AG (SWX:SOON) acquired remaining 50% stake in SilentCloud from Aureliym GmbH. Sonova Holding AG (SWX:SOON) acquired remaining 50% stake in SilentCloud from Aureliym GmbH on December 16, 2025. By bringing SilentCloud’s development in-house, Sonova fully integrates digital tinnitus therapy into its hearing care ecosystem and plans to expand the solution to new markets. The company is also working with national healthcare authorities to explore prescription and reimbursement options, making advanced tinnitus management accessible to more people.
Sonova Holding AG (SWX:SOON) completed the acquisition of remaining 50% stake in SilentCloud from Aureliym GmbH on December 16, 2025. Reported Earnings • Nov 17
First half 2026 earnings released: EPS: CHF3.16 (vs CHF3.50 in 1H 2025) First half 2026 results: EPS: CHF3.16 (down from CHF3.50 in 1H 2025). Revenue: CHF1.82b (down 1.0% from 1H 2025). Net income: CHF188.5m (down 9.6% from 1H 2025). Profit margin: 10% (down from 11% in 1H 2025). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Medical Equipment industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 6% per year. Announcement • Oct 22
Sonova Holding AG Expands AI Leadership with Innovations Debuting at EUHA 2025 Sonova Holding AG announced that it has been redefining hearing technology with the industry's only purpose-built AI chip for speech enhancement in noise with the launch of Sphere Infinio last year. With more than 4.5 million neural connections, Sonova's proprietary DEEPSONIC chip mimics how the human brain processes auditory information. These neural connections act like virtual neurons and are trained with an unprecedented 22 million sound scenes to recognize patterns in sound - especially human speech. This performance is validated through over twenty clinical studies conducted in real-world environments and in collaboration with leading academic institutions. Infinio Ultra - a class of its own in performance, comfort and ease of maintenance. The new Infinio Ultra product range builds on the innovations introduced last year, bringing even more benefits to wearers and hearing care professionals alike. Containing key patented elements across the portfolio, it is another demonstration of Sonova's leadership in innovation (currently, Sonova owns more than 1,900 active granted patents and design rights). Infinio Ultra offers: Fast adaptability: The upgraded operating system AutoSense OStm 7.0 is trained on 18x more environments and adapts 24% more precisely, detecting sound environments automatically. Simple and reliable universal connectivity: The new one-step pairing of Phonak devices to virtually any Bluetooth device, incl. smartphones and tablets, makes the setup effortless. The system supports eight Bluetooth devices, with two active connections at once. Easy use: The new, patented EasyGuard, a break-through wax-management system, is mechanically sealed for extra protection with a membrane that is acoustically transparent, and it's simple to wipe clean. Designed so that hearing aid wearers shouldn't have to change wax filters, it means less fuss and up to 38% fewer service visits. Clear speech for longer: Infinio Ultra Sphere now provides Spheric Speech Clarity 2.0 with all-day performance on a single charge, even for active users in demanding, noisy environments, due to 30% higher efficiency. Announcement • Sep 23
Sonova Holding AG(SWX:SOON) dropped from Swiss SMI Index Sonova Holding AG has been dropped from the Swiss SMI Index Announcement • Sep 03
Sonova Holding AG to Report Fiscal Year 2026 Results on May 18, 2026 Sonova Holding AG announced that they will report fiscal year 2026 results on May 18, 2026 New Risk • Jul 07
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.9% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Announcement • Jun 12
Sonova Holding AG Announces Board and Committee Changes The shareholders formally approved the discharge of the members of the Board of Directors and the Management Board for the 2024/25 financial year. Gilbert Achermann independent member of the Board of Directors, was newly elected as Chair, succeeding Robert F. Spoerry, who did not stand for re-election due to approaching the age limit stipulated in the Organizational Regulations of Sonova Holding AG. Laura Stoltenberg was newly elected as an independent member of the Board of Directors. In addition, Gregory Behar was newly elected as member of the Nomination & Compensation Committee. Upcoming Dividend • Jun 06
Upcoming dividend of CHF4.40 per share Eligible shareholders must have bought the stock before 13 June 2025. Payment date: 17 June 2025. Payout ratio is a comfortable 49% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of Swiss dividend payers (3.8%). Higher than average of industry peers (0.8%). Declared Dividend • May 15
Dividend increased to CHF4.40 Dividend of CHF4.40 is 2.3% higher than last year. Ex-date: 13th June 2025 Payment date: 17th June 2025 Dividend yield will be 1.6%, which is higher than the industry average of 0.7%. Sustainability & Growth Dividend is well covered by both earnings (49% earnings payout ratio) and cash flows (40% cash payout ratio). The dividend has increased by an average of 8.8% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 42% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • May 14
Sonova Holding AG, Annual General Meeting, Jun 10, 2025 Sonova Holding AG, Annual General Meeting, Jun 10, 2025, at 10:00 W. Europe Standard Time. Reported Earnings • May 12
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: CHF10.81. Revenue: CHF3.87b (up 6.6% from FY 2024). Net income: CHF547.0m (down 9.0% from FY 2024). Profit margin: 14% (down from 17% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 3.5%. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 7.6% growth forecast for the Medical Equipment industry in Switzerland. Buy Or Sell Opportunity • Mar 26
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 10% to CHF265. The fair value is estimated to be CHF331, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.4% over the last 3 years. Earnings per share has declined by 3.2%. For the next 3 years, revenue is forecast to grow by 6.6% per annum. Earnings are also forecast to grow by 10% per annum over the same time period. Announcement • Mar 11
Sonova Holding AG to Report Fiscal Year 2025 Final Results on May 13, 2025 Sonova Holding AG announced that they will report fiscal year 2025 final results on May 13, 2025 Announcement • Jan 16
Phonak Expands Infinio Portfolio with Two New Custom Hearing Aids Phonak announced the expansion of its highly acclaimed Infinio technology platform with the introduction of two new in-the-ear (ITE) hearing aids: Virto Titanium Infinio; Virto 10 NW O Infinio. These custom hearing aids now feature the advanced Infinio platform, bringing enhanced discretion, personalization, and sound quality to Phonak's proven in-the-ear solutions. The new Virto Infinio products elevate the Infinio portfolio by delivering unparalleled customization and advanced technology: World's First Custom Hearing Aids with Phonak SmartSpeech Technology--Powered by AutoSense OS 6.0, these hearing aids adapt seamlessly to changing environments to optimize speech understanding and listening comfort. Precision Fit with APD 3.0--Advanced software ensures the first fitting is the right fit, enhancing the user experience from day one. The Infinio platform offers remarkable improvements in exceptional sound quality from the first moment and achieves 93% user preference from the first fit compared to leading competitors. Biometric Calibration--Tailors the hearing aids to the user's unique ear anatomy, providing a truly personalized experience. Sleek, Discreet Design--The compact form factor appeals to users seeking a virtually invisible solution that aligns with modern aesthetic preferences. Comfort and discreet design for a modern lifestyle. Phonak's Virto Infinio hearing aids are designed for individuals seeking a comfortable, discreet solution that does not compromise on sound quality. With titanium shells that are 15 times stronger than traditional acrylic, these devices feature walls that are 50% thinner, allowing for a more compact and unobtrusive design. Their custom fit ensures they remain secure and comfortable, even when wearing glasses or masks, addressing common user concerns. Announcement • Jan 09
Sonova Holding AG Announces Board Retirements Sonova Holding AG announced Stacy Enxing Seng, after a long tenure, will not stand for re-election. Lukas Braunschweiler, a member of the board since 2018, will not stand for re-election due to approaching the age limit as stipulated in the Organizational Regulations of the company. The current Chair, Robert Spoerry will also retire from his board duties due to reaching the age limit, as previously communicated. Reported Earnings • Nov 21
First half 2025 earnings released: EPS: CHF3.50 (vs CHF4.11 in 1H 2024) First half 2025 results: EPS: CHF3.50 (down from CHF4.11 in 1H 2024). Revenue: CHF1.83b (up 4.6% from 1H 2024). Net income: CHF208.6m (down 15% from 1H 2024). Profit margin: 11% (down from 14% in 1H 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Medical Equipment industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 5% per year. Announcement • Oct 29
Sonova Holding AG to Report First Half, 2026 Results on Nov 18, 2025 Sonova Holding AG announced that they will report first half, 2026 results on Nov 18, 2025 Buy Or Sell Opportunity • Sep 24
Now 21% undervalued Over the last 90 days, the stock has risen 6.1% to CHF288. The fair value is estimated to be CHF362, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.2% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 6.4% per annum. Earnings are also forecast to grow by 8.5% per annum over the same time period. Announcement • Aug 06
Phonak Elevates Sound Quality with New Infinio Portfolio, Introducing A Paradigm Shift with Real-Time AI for Speech Clarity in Noise in Audéo Sphere Infinio Phonak, a Sonova brand, launched a new family of hearing aids based on the innovative Infinio platform, including the Audéo Sphere Infinio. It is the world’s first hearing aid powered by a dedicated real-time AI chip for speech-from-noise separation. Speech understanding in background noise remains the biggest challenge for people with hearing loss. This technology provides unprecedented speech clarity from any direction, with an unparalleled improvement in SNR in noise of 10dB. The Infinio platform offers remarkable improvements in: Exceptional Sound Quality from the first moment: Infinio achieves 93% user preference from the first fit compared to leading competitors 45% reduction in listening effort. 21% less fatigue. 61% improvement in speech understanding (when combined with Roger ON), connectivity: Enables uninterrupted hands-free calls and streaming across twice the distance, compatible with all Bluetooth-enabled devices. Durability: Swiss-engineered to withstand everyday challenges Audéo Sphere Infinio: A Paradigm shift enabling clear speech in noise Clear speech from any direction, Building on the Infinio platform, the Audéo Sphere Infinio addresses the number one challenge of speech understanding in noise with a new paradigm-shifting approach. With 53 times more processing power versus existing industry chips, it overcomes the current constraints of processing power to unleash the full potential of artificial intelligence. In addition to the ERA chip, the Audéo Sphere Infinio is powered by a dedicated, proprietary chip called DEEPSONIC; a world-first, real-time AI sound processing chip. Key features include: Spheric Speech Clarity: Clear speech from any direction instantly. Speech from Noise Separation: Advanced AI separates speech from unwanted noise. Signal-to-Noise Ratio Improvement: Achieves an unparalleled SNR improvement of 10dB for better speech understanding in noisy environments, superior to competitor devices by up to 3.7dB. Users are two to three times more likely to understand speech from any direction compared to the two leading competitors. Real-Time AI sound processing with DEEPSONIC chip Phonak’s proprietary DEEPSONIC chip is the first of its kind, providing real-time AI processing to instantly separate speech from background noise. Unlike existing technologies, DEEPSONIC offers dynamic, real-time adjustments, allowing users to engage in conversations from any direction. The chip’s AI architecture includes: Deep Neural Network: 4.5 million neural connections trained with over 22 million sound samples. Unprecedented Processing Power: with 21 times more memory and 4 times more power efficiency, this chip is 53 times more powerful than existing chips and is capable of performing 7,700 million operations per second. “We are incredibly excited to bring the Audéo Sphere Infinio to their users. This is more than just a hearing aid; it's a game-changer for anyone struggling with hearing in noisy environments,” says Robert Woolley, Group Vice President Hearing Instruments at Sonova. Comprehensive Infinio Portfolio, Phonak also introduces a comprehensive portfolio of hearing aids with some products available to order by hearing care professionals starting August 7. These devices are based on the Next-Gen Infinio platform, featuring: Audéo Sphere Infinio: Receiver-In-the-Canal, unique dual chip technology inside, ERA and DEEPSONIC, the world’s first hearing aid with a dedicated AI chip for unprecedented speech clarity in noise. Audéo R Infinio: RIC form factor with ultra-responsive ERA chip inside, delivering exceptional sound quality and connectivity. CROS R Infinio: For unaidable hearing loss in one ear, CROS R is used in combination with Phonak Audéo, offering exceptional sound quality and connectivity as well as increased battery runtime. Virto R Infinio: Phonak’s first rechargeable custom hearing aid (In-The-Ear/ITE) offering exceptional sound quality and connectivity. Board Change • Jul 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 4 highly experienced directors. Independent Director Julie Tay was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Upcoming Dividend • Jun 06
Upcoming dividend of CHF4.30 per share Eligible shareholders must have bought the stock before 13 June 2024. Payment date: 17 June 2024. Payout ratio is a comfortable 43% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of Swiss dividend payers (4.1%). Higher than average of industry peers (0.7%). Reported Earnings • May 16
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2024 results: EPS: CHF10.08 (down from CHF10.75 in FY 2023). Revenue: CHF3.63b (down 3.0% from FY 2023). Net income: CHF601.0m (down 7.2% from FY 2023). Profit margin: 17% (in line with FY 2023). Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) exceeded analyst estimates by 5.6%. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Medical Equipment industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has remained flat. Declared Dividend • May 16
Dividend of CHF4.30 announced Shareholders will receive a dividend of CHF4.30. Ex-date: 13th June 2024 Payment date: 17th June 2024 Dividend yield will be 1.4%, which is higher than the industry average of 0.7%. Sustainability & Growth Dividend is well covered by both earnings (43% earnings payout ratio) and cash flows (41% cash payout ratio). The dividend has increased by an average of 10% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 38% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Nov 24
First half 2024 earnings released: EPS: CHF4.11 (vs CHF4.81 in 1H 2023) First half 2024 results: EPS: CHF4.11 (down from CHF4.81 in 1H 2023). Revenue: CHF1.75b (down 5.1% from 1H 2023). Net income: CHF249.6m (down 14% from 1H 2023). Profit margin: 14% (down from 16% in 1H 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Medical Equipment industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Announcement • Nov 21
Sonova Holding AG Provides Earnings Guidance for the Financial Year 2023/24 Sonova Holding AG provided earnings guidance for the financial year 2023/24. For the period, the company continues to expect consolidated sales to grow by 3%-7% at constant exchange rates. Announcement • Nov 11
Sonova Holding AG to Report First Half, 2025 Results on Nov 19, 2024 Sonova Holding AG announced that they will report first half, 2025 results on Nov 19, 2024 Announcement • Oct 02
Sonova Holding AG to Report Fiscal Year 2024 Results on May 14, 2024 Sonova Holding AG announced that they will report fiscal year 2024 results on May 14, 2024 Announcement • Jun 22
Sonova Holding Ag Announces the Upcoming US Launch of Sennheiser All-Day Clear Sonova Holding AG announced the upcoming US launch of Sennheiser All-Day Clear, a new self-fitting hearing aid which provides consumers with the simplicity of an over-the-counter (OTC) purchase alongside optional support from a hearing care professional (HCP). This further extends the offering of Sennheiser-branded solutions to cover a broad spectrum of early hearing needs, from prevention and situational support through to OTC hearing aids. Sennheiser All- Day Clear and other solutions from this range will be available to US HCP customers to help them build relationships with consumers earlier. Approved by the US Food and Drug Administration (FDA) as an OTC hearing aid, Sennheiser All- day Clear will give US consumers access to powerful assistive hearing technology and self-fitting features. The device is available in two unique designs and consumers can customize it, guided by the intuitive All-Day? Clear app. With the goal of simplifying consumers' lives, music can be streamed from Bluetooth enabled devices, including iOS and AndroidT mobile phones. Furthermore, those consumers seeking the peace of mind that a local HCP can provide have the option to purchase the In-Clinic Care Package. Powered by Sonova technology, the hearing aids feature intelligent scene detection that monitors the person's environment for seamless optimization of speech and music, all provided by a compact rechargeable device. All-Day Clear is part of a broader range of Sennheiser- branded hearing solutions: A growing range of early entry devices, which are designed to provide hearing support in specificsituations, such as understanding speech in a noisy restaurant with Conversation Clear Plus, or on TV with TVClear. Sonova is currently expanding their distribution further, with two dedicated options for its HCP customers (ConC 400 and TVS 200 respectively). The SoundProtex and SoundProtex Plus, high-fidelity hearing protection earplugs which use advanced membrane filter technology to help prevent hearing damage at concerts and loud environments. Announcement • Jun 13
Sonova Holding AG, Annual General Meeting, Jun 11, 2024 Sonova Holding AG, Annual General Meeting, Jun 11, 2024. Upcoming Dividend • Jun 07
Upcoming dividend of CHF4.60 per share at 1.9% yield Eligible shareholders must have bought the stock before 14 June 2023. Payment date: 20 June 2023. Payout ratio is a comfortable 43% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of Swiss dividend payers (4.3%). Higher than average of industry peers (0.7%). Reported Earnings • May 19
Full year 2023 earnings released: EPS: CHF10.75 (vs CHF10.42 in FY 2022) Full year 2023 results: EPS: CHF10.75. Revenue: CHF3.74b (up 11% from FY 2022). Net income: CHF647.5m (flat on FY 2022). Profit margin: 17% (down from 19% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Medical Equipment industry in Switzerland. Buying Opportunity • Feb 27
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 2.7%. The fair value is estimated to be CHF295, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.8% over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 6.0% per annum. Earnings is also forecast to grow by 8.9% per annum over the same time period. Buying Opportunity • Feb 01
Now 22% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be CHF292, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.8% over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 6.0% per annum. Earnings is also forecast to grow by 9.0% per annum over the same time period. Announcement • Jan 12
Sonova Holding AG to Report Q2, 2024 Results on Nov 21, 2023 Sonova Holding AG announced that they will report Q2, 2024 results on Nov 21, 2023 Announcement • Jan 07
Sonova Launches Conversation Clear Plus Earbuds, Expanding into the New Category of Early Entry Hearing Solutions Sonova Holding AG unveiled the launch of the Sennheiser Conversation Clear Plus earbuds, a new speech-enhanced hearable to help consumers improve their comprehension in noisy environments. This launch marks an importantmilestone for Sonova's Consumer Hearing business in establishing a new category of early entry hearing solutions for consumers. Many people find it difficult to clearly understand conversations in noisy environments, such as in a busy restaurant or on a loud street. Conversation Clear Plus earbuds can be used whenever these consumers want effortless clear conversations. This is achieved thanks to advanced Sonova technologies and audiological expertise integrated into the Conversation Clear Plus earbuds. An independent study showed 95% of users experienced significant speech enhancement in noisy situations when using the product.1 An app permits Conversation ClearFor more.